ArticleInternational journal of public health2011
A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.
Article in International journal of public health, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.BMC public health · 2017Pooled it
- Article
- Article
- Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.BMC public health · 2017Article
- Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya.Cost effectiveness and resource allocation : C/E · 2017Article
- Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China.BMC cancer · 2016Article
- Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China.BMC cancer · 2016Article
- HPV-FASTER: broadening the scope for prevention of HPV-related cancer.Nature reviews. Clinical oncology · 2016Review
- Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran.Iranian journal of pharmaceutical research : IJPR · 2015Article
- Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.BMC public health · 2014Article
- Practices and opinions regarding HPV vaccination among French general practitioners: evaluation through two cross-sectional studies in 2007 and 2010.International journal of public health · 2014Article
- A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.Human vaccines & immunotherapeutics · 2013Article
- Modeling preventative strategies against human papillomavirus-related disease in developed countries.Vaccine · 2012Review
- Public health impact of human papillomavirus vaccination on prevention of cervical cancer in France.International journal of public health · 2012Article
- Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed at evaluating the cost-effectiveness of human papillomavirus virus (HPV) vaccination in France, using a generally applicable succinct cohort model.
methodsA lifetime Markov cohort model, adapted to the French setting, simulate the natural history of oncogenic HPV infection towards cervical cancer (CC). Additional modules account for the effects of screening and vaccination. The girls' cohort is vaccinated at age 12 and follows current screening. Costs and outcomes (discounted at 3 and 1.5%, respectively) were compared with a cohort receiving screening alone.
resultsThe model results agreed well with real-life data. Vaccination in addition to screening would substantially reduce the incidence of and mortality from CC, compared with screening alone, at an estimated cost-effectiveness of <euro>9,706 per quality-adjusted-life-year. Sensitivity analysis showed that the discount rate and the parameters related to the disease history have the largest impact on the results.
conclusionThis succinct cohort model indicated that HPV vaccination would be a cost-effective policy option in France. It uses readily available data and should be generally applicable to the evaluation of HPV vaccination in a variety of countries and settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.